Recent research from reputation data specialist RepTrak (Boston) indicates that the pharma industry had the largest year-over-year reputational improvement of any sector, according to its roundup of top 100 corporations. The sector saw significant gains in consumers’ perception of its citizenship and governance. Now ranked eighth overall, the pharma industry came in just ahead of […]
Bristol-Myers Squibb Co.
NIH launches drug trial for deadly cytokine storm
The National Institutes of Health today launched a Phase 3 clinical trial to evaluate three immune modulator drugs in hospitalized adults with COVID-19. Some COVID-19 patients experience an immune response in which the immune system unleashes proteins that trigger inflammation, otherwise known as a cytokine storm, which can lead to acute respiratory distress syndrome, multiple […]
iRhythm touts AFib study
iRhythm Technologies (NSDQ:IRTC) announced that it is participating in a new Bristol-Myers Squibb–Pfizer (NYSE:PFE) Alliance study for reducing stroke by screening for undiagnosed atrial fibrillation in elderly individuals. The goal of the “Guard-AF” study is to determine if earlier detection of AFib can impact the rate of stroke through screening previously undiagnosed people who are at least […]
Fitbit inks cardiovascular monitoring deal with pharma alliance
The Bristol-Myers Squibb (NYSE:BMY)-Pfizer (NYSE:PFE) Alliance said today that it is working with Fitbit (NYSE:FIT) to improve earlier detection of atrial fibrillation in individuals with an increased risk of stroke. Fitbit and the alliance plan to work together on the development of educational content and guidance in support of people at increased risk for Afib. Fitbit is seeking […]
Taris Bio, Bristol-Myers Squibb launch bladder cancer trial
Taris Biomedical has announced the dosing of the first patient in a study of its TAR-200 system plus a programmed immune checkpoint inhibitor for the treatment of muscle-invasive bladder cancer (MIBC). The TAR-200 system continuously delivers the chemotherapy drug gemcitabine in the bladder for multiple weeks. The combination with Bristol-Myers Squibb’s Opdivo (nivolumab) will be assessed for […]
Report: Pharma companies kick off new year with price hikes
Major pharmaceutical firms started the new year by hiking the prices of hundreds of drugs, according to a new study published by Rx Savings Solutions. First reported in The Wall Street Journal, the study found that the average price increase taken by more than three dozen companies was roughly 6.3%. Get the full story at our […]
Sanuwave confirms acting CEO Richardson as company head | Personnel Moves – December 12, 2018
Sanuwave said late last month that it lifted acting CEO and board chair Kevin Richardson to a permanent position in the corner office. Richardson joined the Suwanee, Ga.-based company in 2009 as board chair, and has served as acting CEO since 2014. He also served as managing partner of investment management firm Prides Capital from […]
Motus GI taps Moran as CEO | Personnel Moves – September 25, 2018
Motus GI said today that it named Timothy Moran as its new chief executive officer, effective October 1, replacing former CEO Mark Pomeranz who will assume the role of president and COO. Moran has previously served ConvaTec‘s (LON:CTEC) Americas president and helped lead the company through its initial public offering in 2016. Prior to ConvaTec, Moran spent […]
New Abingworth fund beats expectations
Lifesciences investment group Abingworth Bioventures has closed its latest fund, Abingworth Bioventures VII (ABV VII) at $315 million. The fund — Abingworth’s 12th invested in companies in Europe and the U.S. — exceeded its target of $300 million. The firm has more than $1.2 billion under management. The fund invests broadly across all stages of development, […]
Bristol-Myers Squibb, Illumina to develop companion diagnostics for immunotherapies
Bristol-Myers Squibb (NYSE:BMY) is joining forces with Illumina (NSDQ:ILMN) to develop and commercialize diagnostic tests to support Bristol’s portfolio of cancer drugs. The companies announced last week that they plan to develop an assay to measure predictive genomic biomarkers, like tumor mutation burden, that could help doctors identify patients that will benefit from Bristol’s immunotherapies. Get the full […]
EU committee backs dosing changes for Bristol-Myers Squibb’s immunotherapy
A committee for the European Union’s pharmaceutical regulatory agency backed changes to the dosing schedule for Bristol-Myers Squibb‘s (NYSE:BMY) Opdivo cancer drug, the company touted today. The Committee for Medicinal Products for Human Use recommended that the European Commission approve a dosing schedule of 480-mg infused over 60 minutes every four weeks as an option for […]
